Novartis (Syntometrine Drug) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Novartis (Syntometrine Drug) General Information

Description

An obstetric combination drug. The drug is used in the final stage of labor and the components are synthetically produced oxytocin, a human hormone produced in the hypothalamus and ergometrine, an alpha-adrenergic, dopaminergic and serotonin (5-HT2) receptor agonist.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • Basel
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (Syntometrine Drug) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (Syntometrine Drug)‘s full profile, request access.

Request a free trial

Novartis (Syntometrine Drug) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (Syntometrine Drug)‘s full profile, request access.

Request a free trial